In a pilot study of 34 diabetic patients with confirmed atherosclerosis, dulaglutide significantly reduced blood markers associated with unstable arterial plaque, suggesting cardiovascular protective effects beyond blood sugar control.
PTX3 and MMP-9 significantly reducedTwo key biomarkers of atherosclerotic plaque instability were significantly lowered after dulaglutide treatment in diabetic patients with confirmed arterial plaque buildup.
What the researchers found
Dulaglutide treatment produced significant reductions in two key biomarkers of atherosclerotic plaque instability: pentraxin 3 (PTX3) and matrix metalloproteinase-9 (MMP-9). Both markers are associated with plaque vulnerability — the likelihood that a fatty deposit in an artery will rupture and cause a heart attack or stroke.
The study also documented significant improvements in anthropometric measurements, blood pressure, fasting glucose, and HbA1c levels (median baseline 8.8%), demonstrating that dulaglutide's cardiovascular benefits may operate through multiple pathways simultaneously.
Why it matters
Heart attacks and strokes caused by unstable arterial plaques account for over half of all diabetes-related deaths. If GLP-1 receptor agonists like dulaglutide can stabilize these plaques — not just improve blood sugar — it would represent a major additional benefit of these increasingly popular diabetes drugs and could change how clinicians prioritize them for high-risk cardiovascular patients.
How the study worked
This was an interventional pilot study involving 34 participants aged 41-81 years (average age 61) with type 2 diabetes, dyslipidemia, and atherosclerosis confirmed by B-mode ultrasonography. All participants were started on dulaglutide treatment, and researchers measured levels of four atherosclerosis-related biomarkers — PTX3, copeptin, MMP-9, and lipoprotein(a) — before and after treatment.
What this study cannot tell us
This was a small pilot study with only 34 participants and no control group receiving placebo, making it impossible to rule out that the biomarker improvements were simply due to better blood sugar control or other lifestyle changes. The abstract does not specify the treatment duration or provide exact p-values for all comparisons. Larger randomized controlled trials are needed to confirm these findings.
How to read the evidence
This is a small pilot study (n=34) without a placebo control group. While it provides intriguing preliminary evidence of plaque-stabilizing effects, the lack of randomization and control limits causal conclusions. The findings are hypothesis-generating and warrant confirmation in larger trials.
When this study was published
Published in 2024, this study is recent and reflects current clinical use of GLP-1 receptor agonists. The biomarkers studied (PTX3, MMP-9) are well-established in cardiovascular research, making the findings relevant to ongoing investigations of GLP-1 drugs' cardiovascular benefits.
The bigger picture
GLP-1 receptor agonists have been gaining recognition for cardiovascular benefits beyond glucose control, with large trials like LEADER and REWIND showing reduced cardiovascular events. This pilot study adds mechanistic insight by identifying specific plaque-stabilizing biomarker changes, helping explain how these drugs may protect the heart and blood vessels at a molecular level.
Questions still open
- Do the reductions in plaque instability biomarkers translate to fewer actual heart attacks and strokes in dulaglutide-treated patients?
- Are these plaque-stabilizing effects unique to dulaglutide or shared across all GLP-1 receptor agonists?
- Would combining dulaglutide with statin therapy produce additive benefits on plaque stability?
Common questions
What is dulaglutide and how does it work?
What makes an atherosclerotic plaque 'unstable' and why is that dangerous?
Read the original research
Influence of Dulaglutide on Serum Biomarkers of Atherosclerotic Plaque Instability: An Interventional Analysis of Cytokine Profiles in Diabetic Subjects-A Pilot Study.
Medicina (Kaunas, Lithuania), 60(6)
Citation
Hachuła, Marcin; Kosowski, Michał; Basiak, Marcin; Okopień, Bogusław. (2024). Influence of Dulaglutide on Serum Biomarkers of Atherosclerotic Plaque Instability: An Interventional Analysis of Cytokine Profiles in Diabetic Subjects-A Pilot Study.. Medicina (Kaunas, Lithuania), 60(6). https://doi.org/10.3390/medicina60060908